News & Updates
Filter by Specialty:
Semaglutide trumps liraglutide for weight loss in nondiabetic overweight or obese patients
Nondiabetic adults with overweight or obesity lost more weight when treated with once-weekly semaglutide than once-daily liraglutide, as demonstrated by results of the phase IIIb STEP* 8 trial.
Semaglutide trumps liraglutide for weight loss in nondiabetic overweight or obese patients
07 Apr 2022
Anaphylaxis after COVID mRNA vaccination relatively rare
Anaphylactic reactions warranting treatment after receipt of COVID-19 mRNA vaccinations appear to be relatively rare, according to a US study presented at AAAAI 2022.
Anaphylaxis after COVID mRNA vaccination relatively rare
06 Apr 2022
Add-on amantadine lessens “off” episodes in Parkinson’s disease
A delayed release/extended release (DR/ER) formulation of amantadine can help reduce breakthrough symptoms in Parkinson’s disease patients when the effect of levodopa therapy wears off, as shown in a recent study.
Add-on amantadine lessens “off” episodes in Parkinson’s disease
06 Apr 2022
Prophylactic anticoagulants, pharmacy oversight lower VTE risk in multiple myeloma
Treatment with a guideline-based thromboprophylaxis in multiple myeloma patients and the addition of pharmacy oversight to risk assessment can help reduce the risk of venous thromboembolism (VTE), suggests a recent study.
Prophylactic anticoagulants, pharmacy oversight lower VTE risk in multiple myeloma
06 Apr 2022
Relapsed/refractory multiple myeloma patients burdened with poor survival, high costs
Patients with relapsed/refractory multiple myeloma (RRMM) are at greater risk of adverse events (AEs), have low overall survival (OS), and suffer a substantial economic burden, reports a study, which suggests the need for effective treatment options.
